Big Pharma Convalesces
Big drug manufacturers are attracting strong buying interest this spring, as part of a quiet rotation into slower-moving but higher-yielding instruments. Look for this bullish trend to continue into the summer months, with market players seeking out stocks that are less dependent on the latest economic headline or European bond auction.
These blue-chip behemoths have lagged badly since the bear market ended in 2009, at least until this year, because fast-growth issues have offered the best way to rebuild broken equity. In fact, traders and investors are just now rediscovering the virtues of the pharmaceutical companies, and the sector's revival could last well into this decade....587 more words left in this article. To read them, just click below and try Real Money FREE for 14 days.
There’s no substitute for a trading floor to get great ideas, so Jim Cramer created a better one at Real Money and blogs there exclusively. We then added legendary hedge fund manager, Doug Kass, with his exclusive Daily Diary and best investing ideas. Staffed with more than 4 dozen investing pros, money managers, journalists and analysts, Real Money Pro gives you a flood of opinions, analysis and actionable trading advice found nowhere else, and allows you to interact directly with each expert.
Already a Subscriber? Please login.